Axis inhibition protein 2 (AXIN2) (AXIN2)

Axis inhibition protein 2 (Axin-2) is a critical scaffold protein that serves as a negative regulator of the canonical Wnt/beta-catenin signaling pathway. It functions as a rate-limiting component of the beta-catenin destruction complex, which includes Adenomatous Polyposis Coli (APC) and Glycogen Synthase Kinase 3 beta (GSK3B), facilitating the phosphorylation and subsequent proteasomal degradation of beta-catenin (UniProt, O15169). Because AXIN2 is itself a transcriptional target of the Wnt pathway, it participates in a robust negative feedback loop that maintains pathway homeostasis and prevents over-activation (PubMed, PMID: 10330177). Dysregulation or mutations in the AXIN2 gene are strongly linked to various malignancies, particularly colorectal cancer, as well as developmental defects such as oligodontia (tooth agenesis) (NCBI Gene, 8313). In the context of drug development, Axin-2 is a primary target for stabilization via tankyrase inhibitors, which prevent its degradation and thereby suppress oncogenic Wnt signaling in cancer cells (PubMed, PMID: 19759582). While these inhibitors have shown significant preclinical promise, their therapeutic window is limited by safety concerns related to the essential role of Wnt signaling in normal tissue regeneration, particularly in the gastrointestinal tract (PubMed, PMID: 24014026).

Other names

ConductinAxin-like proteinAxilAXIN2

Stabilization of the beta-catenin destruction complex by inhibiting tankyrase-mediated poly-ADP-ribosylation and subsequent proteasomal degradation of Axin-2, which leads to increased beta-catenin degradation and the suppression of oncogenic Wnt signaling (PubMed, PMID: 19759582).